Skip to main content
Contact Us
Sign Up
Subscriber Sign In
English
日本語
navigation
Search
COVID-19
COVID-19 Daily Update
COVID-19 EventAnalyzer
COVID-19 Stories from Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
EvaluatePharma
EvaluatePharma Vision
Japan Drug Forecasts
European Drug Forecasts
Epi Analyzer
Custom Solutions
Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial team
About Vantage
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
English
日本語
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Policy & Pricing
Policy & Regulation
Pricing
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
ARYx Therapeutics
January 07, 2011
Comeback stories drive small cap risers in 2010
October 21, 2010
Partnering opportunities abound in oncology, CNS and infectious diseases
October 05, 2010
Steady growth the theme for small cap risers after nine months
July 02, 2010
Mixed bag of small cap winners and losers in first half
April 06, 2010
InterMune tops small cap gainers once more in first quarter
February 22, 2010
Broken promises force ARYx to assess strategic options
August 12, 2009
Cumberland cracks open IPO window
July 09, 2009
ARYx under pressure to deliver deals as promised
August 18, 2008
ARYx still walking a tightrope
July 04, 2008
ARYx seeking knight in shining armour
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
February 20, 2020
Vantage Pharma, Biotech & Medtech 2019 in Review
December 17, 2019
Vantage 2020 Preview
Editor's Picks
March 18, 2020
A Covid-19 treatment plan slowly emerges
March 11, 2020
Tiziana takes a deep breath and targets Covid-19
March 12, 2020
Estimating the cost of Covid-19 antiviral development
March 10, 2020
Few groups have developed Covid-19 diagnostics – but this will change
March 20, 2020
Clinical trial delays become reality as Covid-19 risk spreads
